The ovary is covered by a single layer of surface epithelial cells (OSE) where in vivo morphology varies from squamous to cuboidal to low columnar. OSE actively participate in cyclical ovulatory follicular rupture and the subsequent repair [1]. OSE express a variety of peptide hormones, sex steroids, growth factors, and receptors. Many of these biological agents have been implicated in the development of epithelial ovarian carcinomas [2] and sexually transmitted infections [3]. Understanding aberrations in the corresponding cellular pathways is of great clinical importance as they provide useful information regarding OSE cell survival, apoptosis, transformation, and function during disease development and potential markers for disease treatment.
HOSEpiC from ScienCell Research Laboratories are isolated from human ovary. HOSEpiC are cryopreserved at passage one and delivered frozen. Each vial contains >5 x 10^5 cells in 1 ml volume. HOSEpiC are characterized by immunofluorescence with antibodies specific to cytokeratine-14, -18, and -19. HOSEpiC are negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast, and fungi. HOSEpiC are guaranteed to further expand for 5 population doublings under the conditions provided by ScienCell Research Laboratories.
Recommended Medium
It is recommended to use Ovarian Epithelial Cell Medium (OEpiCM, Cat. #7311) for culturing HOSEpiC in vitro.
| 货号 | 849 |
| 产地 | 美国 |
| 缩写 | Human Ovarian Surface Epithelial Cells |
| 规格 | 1μg |
| 用途 | 科研 |
| 储存 | 液氮 |
| 运输 | 干冰 |
2.) Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S, Morris R, Steffes CP, Bouwman DL, Mukarah AR, Weaver DW, Gruber SA, Batchu RB. (2011) "MicroRNA-101 Inhibits Growth of Epithelial Ovarian Cancer by Relieving Chromatin-Mediated Transcriptional Repression of p21waf1/cip1." Pharm Res. 28: 3079-90.
3.) Guo AM, Liu X, Al-Wahab Z, Maddippati KR, Ali-Fehmi R, Scicli AG, Munkarah AR. (2011) "Role of 12-lipoxygenase in regulation of ovarian cancer cell proliferation and survival." Cancer ChemotherPharmacol.68: 1273-83.
4.) Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, K?lai T, Hideg K, Kuppusamy P. (2010) "Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells." Free Radic Biol Med. 48: 1228-35.
5.) Selvendiran K, Tong L, Bratasz A, Kuppusamy ML, Ahmed S, Ravi Y, Trigg NJ, Rivera BK, K?lai T, Hideg K, Kuppusamy P. (2010) "Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts." Mol Cancer Ther. 9: 1169-79.
6.) Selvendiran K, Ahmed S, Dayton A, Kuppusamy ML, Tazi M, Bratasz A, Tong L, Rivera BK, Kalai T, Hideg K, Kuppusamy P. (2010) "Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenylpiperidones: differential cytotoxicity in healthy and cancer cells." Free RadicBiol Med.48: 1228-35.
